Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
IL-13 antagonist and Pseudomonas toxin fusion protein is anticancer
December 12th, 2004
An interleukin-13 receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin exhibited antitumor activity. According to a study from the United States, "We have shown previously that a chimeric fusion protein composed of human interleukin-13 (IL-13) and Pseudomonas exotoxin (PE), termed IL-13 cytotoxin (IL13-PE38), is specifically cytotoxic to various cancer cell lines and primary cell cultures derived from a variety of solid cancers. In addition, we have shown that IL-13 mutant IL-13E13K, in which glutamic acid (E) residue at position 13 of IL-13 molecule was substituted by a lysine (K), is a powerful antagonist of IL-13 and binds...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
